TABLE 3.

Sensitivity analyses for alternative definitions of antiretroviral therapy (ART) attrition: Adjusted hazard ratios (HR), Haiti, 2005–2011^a

	30+ day pharmacy		60+ day pharmacy		90-day visit		180-day visit
Risk factor	HR	P value	HR	P value	HR	P value	HR	P value
Site
Hôpital St. Michel in Jacmel vs.   Hôpital St. Antoine in Jérémie	0.58	< 0.001	0.53	< 0.001	0.46	< 0.001	0.95	0.69
Post vs. pre-earthquake	0.94	0.66	0.77	0.14	0.38	< 0.001	0.51	< 0.01
Gender (male=reference)
Female (not pregnant)	0.99	0.92	1.07	0.67	1.08	0.40	1.02	0.90
Female (pregnant)	1.08	0.71	1.20	0.54	1.16	0.42	1.44	0.22
Age (10 years or more)	1.05	0.20	0.98	0.75	0.92	0.02	0.84	< 0.01
Proximity (same commune=reference)
Adjacent commune	1.69	< 0.001	1.44	0.02	1.03	0.77	1.20	0.25
Non-adjacent commune	1.89	< 0.001	2.37	< 0.001	1.65	< 0.001	2.58	< 0.001
Body mass index (< 18.5=reference)
>18.5	1.19	0.06	1.18	0.21	1.18	0.04	1.40	0.02
Year of ART start (2005-2006=reference)
2007–2008	0.66	< 0.001	0.91	0.56	2.02	< 0.001	1.14	0.36
2009–2010	0.60	< 0.01	1.09	0.71	1.67	< 0.001	0.81	0.41
2011	0.37	< 0.001	0.54	0.13	2.20	< 0.01	0.88	0.77
Baseline CD4 (< 100=reference)
100–249	1.06	0.58	1.01	0.97	1.06	0.54	0.75	0.05
≥ 250	1.15	0.33	0.98	0.92	1.04	0.74	0.78	0.18
ART regimenb (AZT-3TC-EFV=reference)
AZT-3TC-NVP	1.14	0.23	0.94	0.70	0.87	0.16	0.79	0.15
d4T or TDF + 3TC-EFV	0.67	0.10	0.47	0.07	1.01	0.97	1.08	0.81
d4T or TDF + 3TC-NVP	0.86	0.51	0.78	0.45	0.73	0.09	0.66	0.21
non-standard regimens	2.04	0.01	1.04	0.94	0.54	0.07	1.17	0.73
World Health Organization clinical stage (Stage I or II = reference)
Stage III or IV	1.16	0.07	1.19	0.15	1.11	0.13	1.09	0.51
Tuberculosis status (No suspicion, prophylaxis or diagnosis = reference)
Yes	0.91	0.32	0.95	0.75	0.94	0.48	1.03	0.81
Any Stage IV symptom (No=reference)
Yes	0.84	0.22	0.77	0.21	0.94	0.64	1.16	0.47
Pre-ART duration (30 day increase)	0.99	0.01	0.99	0.07	0.99	< 0.01	0.98	0.01
Counseling sessions prior to ART start (None = reference)
1	0.84	0.07	0.92	0.52	1.11	0.22	1.05	0.73
≥ 2	0.74	0.06	0.83	0.42	0.99	0.93	0.92	0.75

^aMain effects model using alternative definitions for ART attrition; items in bold represent statistically significant hazard ratios.

^bART regimen: AZT = zidovudine; 3TC =l amivudine; EFV = efavirenz; NVP = nevirapine; d4T = stavudine; TDF = tenofovir.